相关实验视频

Updated: May 31, 2025

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

Published on: May 22, 2020

杜维利西布是一种新型NFAT抑制剂,可以减轻阿达利穆马布诱导的免疫性

Aboli Bhingarkar¹, Yuyin Wang¹, Keito Hoshitsuki¹

¹Center for Pharmacogenetics and Department of Pharmaceutical Sciences, University of Pittsburgh School of Pharmacy, Pittsburgh, PA, United States.

Frontiers in pharmacology

|January 24, 2025

概括

杜维利西布 (DV) 通过向NFAT,有效地抑制TNFα抑制剂在类风湿性关节炎中的免疫性,提供了一种潜在的替代甲状腺素的替代品. 这种新型的NFAT抑制剂在控制不必要的免疫反应方面表现有前途.

科学领域:

免疫学免疫学免疫学
药理学药理学是指药理学的学科.
类风湿病学类风湿病学

背景情况:

生物免疫性,特别是TNFα抑制剂 (TNFi),阻碍了类风湿性关节炎 (RA) 治疗的有效性.
甲托雷克萨特 (MTX) 减轻了TNFi的免疫性,但有不良影响,需要使用替代策略.
向激活T细胞的核因子 (NFAT) 是防止生物免疫性的一种潜在方法.

研究的目的:

确定和评估一种新的NFAT转录因子的小分子抑制剂.
评估该化合物在预防TNFi免疫性方面的有效性.
探索MTX的替代策略,以管理RA中的TNFi免疫性.

主要方法:

基于结构的NFATC2虚拟查,以确定潜在的抑制剂.
在体外验证化合物对NFAT活性,局部化和DNA结合的影响.
在小鼠体内研究以评估对TNFi免疫性保护.
对T细胞增殖和B细胞抗体分泌的活体评估.

主要成果:

杜维利西布 (DV) 被确定为一种新的NFATC2和NFATC1抑制剂,可以独立于PI3K减弱NFAT活性.
DV干扰了核NFAT与NFAT共识促进序列的结合.
DV显著保护小鼠免受阿达利穆马布免疫性和降低T细胞增殖和B细胞抗体分泌.

结论:

杜维利西布 (DV) 是一种有前途的NFAT抑制剂,可以在不抑制氨酸酸酶活性的情况下预防TNFi免疫性.
DV提供了MTX的潜在替代品,用于减轻对生物制剂的不良免疫反应.
未来开发DV类似物可能对减轻不必要的免疫反应有价值.

关键词:

NFAT (激活T细胞的核因子)这就是Adalimumab.抗药抗体 (ADA) 是一种抗药抗体.双重存在的可能甲基特雷克萨酸盐的使用方法类风湿性关节炎是一种类风湿性关节炎.

更多相关视频

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

Myeloid Innate Signaling Pathway Regulation by MALT1 Paracaspase Activity

Myeloid Innate Signaling Pathway Regulation by MALT1 Paracaspase Activity

Published on: January 7, 2019

相关概念视频

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...